Zydus gets USFDA orphan drug status for beta-thalassemia treatment
Zydus Lifesciences recently received Orphan Drug Designation from the USFDA for its drug Desidustat, aimed at treating beta-thalassemia—a rare blood disorder affecting fewer than 200,000 Americans.
With Orphan Drug Designation, Zydus gets perks like tax breaks and seven years of exclusive marketing if the drug is approved.
Desidustat may reduce reliance on blood transfusions
Desidustat is a medication that may help the body make more red blood cells by increasing erythropoietin levels, tackling the anemia that comes with beta-thalassemia.
Unlike current treatments that often require lifelong transfusions, this drug may help reduce reliance on them by encouraging natural red blood cell production.
Pricing hasn't been announced yet.
Early studies show promise in addressing iron overload, stress
The science behind Desidustat suggests it may lower iron overload and stress in red blood cells—two big issues for people with beta-thalassemia—based on preclinical studies.
Early studies look promising for those who depend on transfusions today, making this a hopeful step forward in rare disease care.